PA
LENZ

Perceptive Advisors’s LENZ Therapeutics LENZ Stock Holding History

Perceptive Advisors’s Portfolio LENZ Stock Details LENZ Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		– Sell
-50,000
Closed -$800K – 129
2025
Q4 		$800K Buy
+50,000
New +$1.46M 0.01% 110
2022
Q2 		– Sell
-46,551
Closed -$1.66M – 126
2022
Q1 		$1.66M Sell
46,551
-74,891
-62% -$4.69M 0.03% 121
2021
Q4 		$10.6M Sell
121,442
-3,571
-3% -$296K 0.16% 90
2021
Q3 		$14.3M Hold
125,013
– – 0.21% 84
2021
Q2 		$26.9M Buy
+125,013
New +$21.8M 0.35% 67

Other funds holding LENZ

RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
AWG
Alpha Wave Global New York $791M AUM 113.77% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
VVM
Versant Venture Management San Francisco, California $141M AUM 190.82% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Squarepoint
Squarepoint New York $85.1B AUM 20.93% 1-Year Est. Return
Aberdeen Group
Aberdeen Group Edinburgh, United Kingdom $61.9B AUM 29.81% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
7IH
72 Investment Holdings Stamford, Connecticut $49.6M AUM 684.72% 1-Year Est. Return

Perceptive Advisors's LENZ Position: Q1 2026 in Review

Perceptive Advisors sold out of LENZ Therapeutics (LENZ) in Q1 2026, closing a stake of 50,000 shares — an estimated $800K sold.

Perceptive Advisors first reported a position in LENZ in Q2 2021 and held it in 5 quarters. The position peaked at $26.9M in Q2 2021. 145 funds tracked by Wall St. Rank hold LENZ as of Q1 2026.

  • Perceptive Advisors reported no remaining LENZ Therapeutics position as of Q1 2026 after selling out during the quarter.
  • Perceptive Advisors sold 50,000 LENZ Therapeutics shares in Q1 2026, an estimated $800K.
  • Perceptive Advisors first reported a position in LENZ Therapeutics in Q2 2021 and held it in 5 quarters.
  • Perceptive Advisors's LENZ Therapeutics position peaked at $26.9M in Q2 2021.
  • 145 funds tracked by Wall St. Rank held LENZ Therapeutics as of Q1 2026.

Based on Perceptive Advisors's 13F filing for Q1 2026, filed 15 May 2026.